Business Services Industry

NeurAxon, Inc. to Present at the BIO National Venture Conference April 1, 2009

Business Wire, March 27, 2009

WALTHAM, Mass. -- NeurAxon, Inc. is pleased to announce that Lawrence Bloch, M.D., J.D., the Company’s Chief Executive Officer, will present at the BIO National Venture Conference taking place March 31 – April 1, 2009 in Boston, MA.

The NeurAxon presentation will be delivered on Wednesday, April 1, 2009 at 10:35am Eastern Time at the Sheraton Boston Hotel.

Dr. Bloch will provide an overview of NeurAxon and its portfolio of novel, proprietary pain therapeutics, including its lead candidate, NXN-188, an oral, first-in-class, selective nNOS inhibitor and 5HT agonist which is currently in development for acute migraine.

About NeurAxon Inc.

NeurAxon Inc. (www.neuraxon.com) discovers and develops next-generation pain therapeutics focused on its first-in-class selective inhibitors of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization.

Copyright Business Wire 2009

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Business Wire